Åslaug Helland
Researcher Next ID · RN-038284
Researcher · Biochemistry, Genetics and Molecular Biology
Oslo, Norway
- Works count
- 525
- Citation count
- 12,442
- H-index
- 55
- i10-index
- 154
Research interests
Publications
Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study
Annals of Oncology · 2018 · https://doi.org/10.1093/annonc/mdy121
Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors
Nature Communications · 2018 · https://doi.org/10.1038/s41467-018-03099-x
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
The Lancet Oncology · 2017 · https://doi.org/10.1016/s1470-2045(17)30679-4
Pan-cancer analysis of somatic copy-number alterations implicates IRS4 and IGF2 in enhancer hijacking
Nature Genetics · 2016 · https://doi.org/10.1038/ng.3722
Inference of Tumor Evolution during Chemotherapy by Computational Modeling and In Situ Analysis of Genetic and Phenotypic Cellular Diversity
Cell Reports · 2014 · https://doi.org/10.1016/j.celrep.2013.12.041
Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids
Nature Communications · 2014 · https://doi.org/10.1038/ncomms4518
Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer
Cancer Discovery · 2011 · https://doi.org/10.1158/2159-8274.cd-11-0005
TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies
The Lancet Oncology · 2009 · https://doi.org/10.1016/s1470-2045(09)70187-1
Gene Expression Programs in Response to Hypoxia: Cell Type Specificity and Prognostic Significance in Human Cancers
PLoS Medicine · 2006 · https://doi.org/10.1371/journal.pmed.0030047
Current projects
No projects listed.